Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial

BACKGROUND: The prostaglandin D(2) (PGD(2)) receptor 2 (DP(2) receptor) pathway is an important regulator of the inflammatory cascade in asthma, which can be stimulated by allergic or non-allergic triggers. Fevipiprant is an oral, non-steroidal, highly selective, reversible antagonist of the DP(2) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Maspero, Jorge, Agache, Ioana Octavia, Kamei, Tadashi, Yoshida, Makoto, Boone, Bryan, Felser, James M., Kawakami, Fernando, Knorr, Barbara, Lawrence, David, Lehmann, Thomas, Wang, Wei, Pedinoff, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666007/
https://www.ncbi.nlm.nih.gov/pubmed/34895218
http://dx.doi.org/10.1186/s12931-021-01904-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666007/
https://www.ncbi.nlm.nih.gov/pubmed/34895218
http://dx.doi.org/10.1186/s12931-021-01904-8

Ejemplares similares